A case-control study: Association between serum neuregulin 4 level and non-alcoholic fatty liver disease
- PMID: 26476959
- DOI: 10.1016/j.metabol.2015.08.013
A case-control study: Association between serum neuregulin 4 level and non-alcoholic fatty liver disease
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is a great health burden. Neuregulin 4 (Nrg4) is a recently identified secret factor that may be associated with NAFLD.
Aim: To investigate the association between serum Nrg4 level and NAFLD by conducting a case-control study.
Method: A total of 174 subjects were included. 87 NAFLD subjects and 87 age- and sex-matched non-NAFLD controls were identified by hepatic ultrasound examination. Anthropometric and biochemical data were measured and recorded. Serum Nrg4 level was evaluated by using enzyme-linked immunosorbent assay. SPSS software was used for statistical analyses.
Results: Compared to the controls, subjects with NAFLD presented with reduced level of serum Nrg4 (0.40 (0.27, 0.55) vs. 0.50 (0.30, 0.81)ng/mL (median (interquartile range)), P=0.029). By multivariate logistic regression analysis, reduced serum levels of Nrg4 were associated with higher NAFLD odds (OR=0.251, 95% confidence interval=0.081-0.779, P=0.017). By dividing the distribution of serum Nrg4 level into quartiles, there was borderline statistical difference of NAFLD prevalence among the four groups (P=0.058). There was no significant difference of serum Nrg4 levels in subjects according to the grades of fatty liver by ultrasound (P=0.080). No statistical difference of serum Nrg4 level was observed between obese and non-obese subjects (P=0.932).
Conclusion: Decreased serum Nrg4 level is prevalent in NAFLD subjects compared to non-NAFLD controls, and is an independent risk factor associated with NAFLD, indicating that Nrg4 might have a protective role in the development of NAFLD.
Keywords: Neuregulin 4; Non-alcoholic fatty liver disease; Obesity.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
Decreased serum neuregulin 4 levels associated with non-alcoholic fatty liver disease in children with obesity.Clin Obes. 2019 Feb;9(1):e12289. doi: 10.1111/cob.12289. Epub 2018 Nov 8. Clin Obes. 2019. PMID: 30411515
-
Is there a role for neuregulin 4 in human nonalcoholic fatty liver disease?PLoS One. 2021 May 14;16(5):e0251822. doi: 10.1371/journal.pone.0251822. eCollection 2021. PLoS One. 2021. PMID: 33989346 Free PMC article.
-
Nrg4 promotes fuel oxidation and a healthy adipokine profile to ameliorate diet-induced metabolic disorders.Mol Metab. 2017 Jun 21;6(8):863-872. doi: 10.1016/j.molmet.2017.03.016. eCollection 2017 Aug. Mol Metab. 2017. PMID: 28752050 Free PMC article.
-
The journey towards physiology and pathology: Tracing the path of neuregulin 4.Genes Dis. 2023 Apr 25;11(2):687-700. doi: 10.1016/j.gendis.2023.03.021. eCollection 2024 Mar. Genes Dis. 2023. PMID: 37692526 Free PMC article. Review.
-
Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies.Obes Rev. 2016 Jun;17(6):510-9. doi: 10.1111/obr.12407. Epub 2016 Mar 28. Obes Rev. 2016. PMID: 27020692 Review.
Cited by
-
The link between serum neuregulin-1 and atherogenic index in type 2 diabetes mellitus.Ir J Med Sci. 2024 Oct;193(5):2209-2216. doi: 10.1007/s11845-024-03711-8. Epub 2024 May 15. Ir J Med Sci. 2024. PMID: 38748196
-
Study of neuregulin-4 levels in newly diagnosed type 2 diabetes mellitus.J Family Med Prim Care. 2023 Nov;12(11):2888-2893. doi: 10.4103/jfmpc.jfmpc_265_23. Epub 2023 Nov 21. J Family Med Prim Care. 2023. PMID: 38186791 Free PMC article.
-
Changes of circulating neuregulin 4 and its relationship with 25-hydroxy vitamin D and other diabetic vascular complications in patients with diabetic peripheral neuropathy.Diabetol Metab Syndr. 2020 May 19;12:42. doi: 10.1186/s13098-020-00550-2. eCollection 2020. Diabetol Metab Syndr. 2020. PMID: 32477429 Free PMC article.
-
Novel secreted regulators of glucose and lipid metabolism in the development of metabolic diseases.Diabetologia. 2024 Dec;67(12):2626-2636. doi: 10.1007/s00125-024-06253-x. Epub 2024 Aug 24. Diabetologia. 2024. PMID: 39180580 Review.
-
Brown and Beige Adipose Tissue: Therapy for Obesity and Its Comorbidities?Endocrinol Metab Clin North Am. 2016 Sep;45(3):605-21. doi: 10.1016/j.ecl.2016.04.010. Endocrinol Metab Clin North Am. 2016. PMID: 27519133 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical